Lv2
156 积分 2024-05-10 加入
Cancer burden and control in China: landscape, trends and challenges
1天前
已完结
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
1年前
已完结
ABCL-579 Zilovertamab Vedotin (ZV) Alone or in Combination With Nemtabrutinib in Relapsed or Refractory (R/R) Aggressive and Indolent B-Cell Malignancies (waveLINE-006): An Open-Label, Phase 2 Basket Study
1年前
已关闭
Potential risk of non-arteritic anterior ischaemic optic neuropathy in semaglutide users: pharmacovigilance insights
1年前
已关闭
皖公网安备34019202002308
